Non-inferiority Comparison of Efficacy and Safety of Penciclovir 10mg/g to Acyclovir 50mg/g in the Treatment of Recurrent Herpes Labialis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Herpes labialis is the most common recurrent manifestation of herpes simplex. The purpose of this study is to check the non-inferiority efficacy and safety of penciclovir 10mg/g as treatment for Herpes Labialis in comparison to acyclovir 50mg/g.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Patients must be able to understand the study procedures agree to participate and give written consent.

Patients with clinical diagnosis of recurrent herpes labialis and are in the prodromal period (stinging, itching, burning and erythema) at the onset of signs / symptoms in the last 12-24 hours;

No history of reaction to topical products;

Exclusion Criteria:

Pregnancy or risk of pregnancy.

Lactation

Use of anti-inflammatory or immunosuppressive drugs (last 30 days prior to the study.)

Sunlight over exposure in the last 15 days.

Any pathology or past medical condition that can interfere with this protocol.

AINH use, hormonal anti-inflammatory, analgesic and immunosuppressive drugs (in the last 30 days and during the study);

Patients with immunodeficiency and/or immunosuppressive disease;

Sunlight exposure in the last 15 days;

Hypersensitivity to components of the formula;

Other conditions deemed reasonable by the medical investigator as to the disqualification of the individual from study participation.